NCT05901285 - Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

November 30, 2026

Conditions

Advanced Solid TumorAdvanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab

Interventions

DRUG

VAX014

Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication

COMBINATION_PRODUCT

Nivolumab or pembrolizumab

VAX014 will be given in combination with Investigator's choice of nivolumab or pembrolizumab.

Trial Locations (8)

RECRUITING

George Washington University, Washington D.C.

RECRUITING

University of Maryland, Baltimore

RECRUITING

Cleveland Clinic, Cleveland

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

RECRUITING

University of Arizona Cancer Center, Tucson

RECRUITING

Dana Farber Cancer Institute, Boston

RECRUITING

Dartmouth Cancer Center, Lebanon

RECRUITING

Atlantic Health System, Morristown